Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Robert M Swift

Showing results (51-60 of 90) with videos related to

Pageof 9
Sort By:
European Journal of Pharmaceutical Sciences : Official Journal of the European Federation for Pharmaceutical Sciences|August 6, 2017
A Phase I randomized clinical trial testing the safety, tolerability and preliminary pharmacokinetics of the mGluR5 negative allosteric modulator GET 73 following single and repeated doses in healthy volunteersCarolina L Haass-Koffler, Kimberly Goodyear, Victoria M Long, et al.
Data in Brief|December 8, 2017
Dataset for Phase I randomized clinical trial for safety and tolerability of GET 73 in single and repeated ascending doses including preliminary pharmacokinetic parametersCarolina L Haass-Koffler, Kimberly Goodyear, Victoria M Long, et al.
Addiction Biology|June 4, 2015
Role of the α1 blocker doxazosin in alcoholism: a proof-of-concept randomized controlled trialGeorge A Kenna, Carolina L Haass-Koffler, William H Zywiak, et al.
Journal of Substance Abuse Treatment|March 26, 2015
Contingent vouchers and motivational interviewing for cigarette smokers in residential substance abuse treatmentDamaris J Rohsenow, Jennifer W Tidey, Rosemarie A Martin, et al.
Experimental and Clinical Psychopharmacology|February 14, 2007
High-dose transdermal nicotine and naltrexone: effects on nicotine withdrawal, urges, smoking, and effects of smokingDamaris J Rohsenow, Peter M Monti, Kent E Hutchison, et al.
The American Journal on Addictions|June 4, 2020
Brief Report: Relationship Between Cotinine Levels and Peripheral Endogenous Concentrations of Oxytocin, β-Endorphin, and Orexin in Individuals With Both Alcohol and Nicotine Use DisordersCarolina L Haass-Koffler, Roberta Perciballi, Zoe E Brown, et al.
Addiction Biology|October 30, 2014
Biobehavioral mechanisms of topiramate's effects on alcohol use: an investigation pairing laboratory and ecological momentary assessmentsRobert Miranda, James MacKillop, Hayley Treloar, et al.
Contemporary Clinical Trials Communications|September 12, 2024
Design and methodology of the first open-label trial of MDMA-assisted therapy for veterans with post-traumatic stress disorder and alcohol use disorder: Considerations for a randomized controlled trialErica Eaton, Christy Capone, Brian J Gully, et al.
Biological Psychiatry|April 30, 2014
Intravenous ghrelin administration increases alcohol craving in alcohol-dependent heavy drinkers: a preliminary investigationLorenzo Leggio, William H Zywiak, Samuel R Fricchione, et al.
Alcohol and Alcoholism (Oxford, Oxfordshire)|June 18, 2014
Translating the semi-structured assessment for drug dependence and alcoholism in the Western Pacific: rationale, study design and reliability of alcohol dependenceAmity E Quinn, Rochelle K Rosen, John E McGeary, et al.
Pageof 9

Showing results (51-60 of 90) with videos related to

Sort By:
Pageof 9
European Journal of Pharmaceutical Sciences : Official Journal of the European Federation for Pharmaceutical Sciences|August 6, 2017
A Phase I randomized clinical trial testing the safety, tolerability and preliminary pharmacokinetics of the mGluR5 negative allosteric modulator GET 73 following single and repeated doses in healthy volunteersCarolina L Haass-Koffler, Kimberly Goodyear, Victoria M Long, et al.
Data in Brief|December 8, 2017
Dataset for Phase I randomized clinical trial for safety and tolerability of GET 73 in single and repeated ascending doses including preliminary pharmacokinetic parametersCarolina L Haass-Koffler, Kimberly Goodyear, Victoria M Long, et al.
Addiction Biology|June 4, 2015
Role of the α1 blocker doxazosin in alcoholism: a proof-of-concept randomized controlled trialGeorge A Kenna, Carolina L Haass-Koffler, William H Zywiak, et al.
Journal of Substance Abuse Treatment|March 26, 2015
Contingent vouchers and motivational interviewing for cigarette smokers in residential substance abuse treatmentDamaris J Rohsenow, Jennifer W Tidey, Rosemarie A Martin, et al.
Experimental and Clinical Psychopharmacology|February 14, 2007
High-dose transdermal nicotine and naltrexone: effects on nicotine withdrawal, urges, smoking, and effects of smokingDamaris J Rohsenow, Peter M Monti, Kent E Hutchison, et al.
The American Journal on Addictions|June 4, 2020
Brief Report: Relationship Between Cotinine Levels and Peripheral Endogenous Concentrations of Oxytocin, β-Endorphin, and Orexin in Individuals With Both Alcohol and Nicotine Use DisordersCarolina L Haass-Koffler, Roberta Perciballi, Zoe E Brown, et al.
Addiction Biology|October 30, 2014
Biobehavioral mechanisms of topiramate's effects on alcohol use: an investigation pairing laboratory and ecological momentary assessmentsRobert Miranda, James MacKillop, Hayley Treloar, et al.
Contemporary Clinical Trials Communications|September 12, 2024
Design and methodology of the first open-label trial of MDMA-assisted therapy for veterans with post-traumatic stress disorder and alcohol use disorder: Considerations for a randomized controlled trialErica Eaton, Christy Capone, Brian J Gully, et al.
Biological Psychiatry|April 30, 2014
Intravenous ghrelin administration increases alcohol craving in alcohol-dependent heavy drinkers: a preliminary investigationLorenzo Leggio, William H Zywiak, Samuel R Fricchione, et al.
Alcohol and Alcoholism (Oxford, Oxfordshire)|June 18, 2014
Translating the semi-structured assessment for drug dependence and alcoholism in the Western Pacific: rationale, study design and reliability of alcohol dependenceAmity E Quinn, Rochelle K Rosen, John E McGeary, et al.
Pageof 9